🇺🇸 FDA

Intelligence Platform

Patents

Browse 52 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12409167

Pharmaceutical combination comprising a selective S1P1 receptor agonist

VANDA PHARMACEUTICALS INC. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12336980

Dosing regimen for a selective S1P1 receptor agonist

VANDA PHARMACEUTICALS INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221610

RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and me

Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12202822

Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical compos

SuZhou Connect Biopharmaceuticals, Inc. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178861

Stabilized liquid and lyophilized ADAMTS13 formulations

Takeda Pharmaceutical Company Limited · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156903

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sick

Takeda Pharmaceutical Company Limited · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958849

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11918638

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11779635

Subcutaneous administration of ADAMTS13

Takeda Pharmaceutical Company Limited · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11739309

CRISPR-Cas12J effector polypeptides and methods of use thereof

The Regents of the University of California · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713462

Modulation of GYS1 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713313

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661593

Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Takeda Pharmaceutical Company Limited · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564979

Stabilized liquid and lyophilized ADAMTS13 formulations

Takeda Pharmaceutical Company Limited · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512078

Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical compos

SuZhou Connect Biopharmaceuticals, Inc. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472772

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370786

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11261444

Organic compositions to treat EPAS1-related diseases

Arrowhead Pharmaceuticals, Inc. · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254666

Compound as GLS1 inhibitor

Medshine Discovery Inc. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236339

Modulation of GYS1 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11230544

Substituted 1,3,4-thiadiazoles as GLS1 inhibitors

Medshine Discovery Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11192886

S1P1 agonist and application thereof

Medshine Discovery Inc. · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191818

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sick

Takeda Pharmaceutical Company Limited · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11185575

Subcutaneous administration of ADAMTS13

Takeda Pharmaceutical Company Limited · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted